Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

The need for a holistic and unbiased approach to develop a more universal vaccine for coronaviruses

Researchers emphasized the need to take on a holistic and unbiased approach to develop a universal vaccine for coronaviruses, including SARS-CoV-2, which is a biomedical priority during the ongoing COVID-19 pandemic.

28 Feb 2022

Vaccination reduces risk of long-COVID

A new study posted on the medRxiv* preprint server investigated the difference between the likelihood of symptoms, 12 weeks after SARS-CoV-2 infection, among individuals who received two COVID-19 vaccination doses and unvaccinated individuals.

27 Feb 2022

A promising new vaccine for SARS-CoV-2 and influenza

Researchers create a vaccine candidate that could protect against both SARS-CoV-2 and IAVs.

27 Feb 2022

Study explores the boosting of SARS-CoV-2 adenovirus vaccine-induced immunity by capsid decoration

Researchers demonstrated that decorating the capsid surface of adenovirus vaccine vectors with a newly discovered protein superglue, DogTag/DogCatcher generates potent SARS-CoV-2-specific humoral and cellular immunity.

24 Feb 2022

SARS-CoV-2 occurrence compared with other respiratory viruses in children with acute respiratory infections

The current study examined the incidence of COVID-19 in children with ARI relative to other respiratory viruses during the second and third waves.

22 Feb 2022

ChAdOx1 vaccine found to protect Syrian hamsters against SARS-CoV-2 variants

Researchers recently evaluated the efficacy of the Oxford ChAdOx1 (AZD 1222/ AZD2816) vaccine against the Omicron, Delta, and Beta variants of SARS-CoV-2 in Syrian hamsters.

17 Feb 2022

Development of multivalent next-generation vaccine strategy against ancestral SARS-CoV-2 and emerging variants

A recent study demonstrated that intranasal (i.n.) delivery of COVID-19 vaccine in murine models elicits greater immune responses against the wildtype SARS-CoV-2 and its variants.

14 Feb 2022

New insights into the effects of COVID-19 vaccination on dialysis patients

Two studies in CJASN offer a better understanding of the effects of COVID-19 vaccination on individuals with kidney failure who are undergoing long-term dialysis.

11 Feb 2022

Study investigates population immunity to SARS-CoV-2 through heterogenous pathways

A new study demonstrates COVID-19 vaccine-specific differences in the antibody responses and memory B-cell immunity in a sample population comprising of 197 vaccinated individuals in Mexico.

11 Feb 2022

PCR data sheds light on the dynamics of interspecies pathogen-pathogen interactions

The new study uses PCR data on 17 different pathogens, collected from clinical samples as part of the Seattle Flu Study, a community-based surveillance study of respiratory viral infections.

8 Feb 2022

Study explores omicron-reactive T- and B- cell responses in COVID-19 vaccine recipients

A new study analyzes neutralizing antibodies and T-cell responses targeting the SARS-CoV-2 D614G, as well as some variants of concern.

7 Feb 2022

Researchers suggest that visible blue light is a safe and variant-agnostic therapy against SARS-CoV-2

In a new study, researchers showed that 425 nm blue light can inactivate all major SARS CoV 2 variants.

4 Feb 2022

Developing post-vaccination SARS-CoV-2 standard reference sera

A new study reports the generation of reference sera reagents that were obtained from subjects vaccinated with one of four COVID-19 vaccines.

1 Feb 2022

Assessing the effects of booster vaccinations against SARS-CoV-2 Omicron variant

In a new study, researchers analyzed the effect of vaccine booster doses against the SARS-CoV-2 Omicron variant.

1 Feb 2022

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

In a new study, a team of researchers developed a vaccine candidate with the SARS-CoV-2 spike (S) glycoprotein coated onto lipid vesicles which resembles virus-like particles.

26 Jan 2022

AMSBIO Expands EU Operations

...

From AMS Biotechnology 26 Jan 2022

Constructing SARS-CoV-2 virus-like particles in tobacco plants for vaccine development

In a study published in the latest issue of the Scientific Reports, a team of researchers constructed virus-like particles (VLPs) composed of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M), envelope (E), and nucleocapsid (N) proteins in tobacco plant using Agrobacterium-mediated delivery.

24 Jan 2022

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

In a recent study posted to the bioRxiv* preprint server, researchers developed a novel bioinformatic algorithm to predict host cleavage targets of the SARS-CoV-2 3C-like protease (3CLPro).

23 Jan 2022

New COVID-19 vaccine promises vaccine equity because it has no patents

Corbevax, a new vaccine against COVID-19, may have better success as a candidate for vaccine equity because it carries no patents, relies on long-established recombinant technology for manufacture and has the support of the US and Indian governments, its makers and health experts say.

21 Jan 2022

Exploring the interactions between multiple respiratory viruses

A recent report explores the dynamics of viral interference between various respiratory viruses in light of the ongoing COVID-19 pandemic.

19 Jan 2022